List of bibliographic references
Number of relevant bibliographic references: 7.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Female |
| 4 | Humans |
| 2 | Adult |
| 2 | Aged |
| 2 | Aged, 80 and over |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 2 | Disease-Free Survival |
| 2 | Doxorubicin (administration & dosage) |
| 2 | Doxorubicin (analogs & derivatives) |
| 2 | Drug Resistance, Neoplasm |
| 2 | Middle Aged |
| 2 | Ovarian Neoplasms (drug therapy) |
| 2 | Ovarian Neoplasms (therapy) |
| 2 | Paclitaxel (administration & dosage) |
| 2 | Polyethylene Glycols (administration & dosage) |
| 2 | Practice Guidelines as Topic |
| 2 | Topotecan (administration & dosage) |
| 2 | Treatment Outcome |
| 1 | Age Factors |
| 1 | Antiangiogenic agent |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 1 | Antineoplastic agent |
| 1 | Bevacizumab |
| 1 | Bevacizumab (administration & dosage) |
| 1 | Bevacizumab (adverse effects) |
| 1 | Cancerology |
| 1 | Chemotherapy |
| 1 | Clinical Trials as Topic (methods) |
| 1 | Combined Modality Therapy |
| 1 | Consensus |
| 1 | Doxorubicin (adverse effects) |
| 1 | Doxorubicin (therapeutic use) |
| 1 | Drug Administration Schedule |
| 1 | Evolution |
| 1 | Human |
| 1 | Hypertension (chemically induced) |
| 1 | Hypertension (physiopathology) |
| 1 | Immunomodulator |
| 1 | Medical Oncology |
| 1 | Neoplasm Recurrence, Local (drug therapy) |
| 1 | Neoplasm Recurrence, Local (therapy) |
| 1 | Neoplasms, Glandular and Epithelial (mortality) |
| 1 | Neoplasms, Glandular and Epithelial (therapy) |
| 1 | Organoplatinum Compounds (pharmacology) |
| 1 | Ovarian Neoplasms (classification) |
| 1 | Ovarian Neoplasms (mortality) |
| 1 | Ovarian Neoplasms (pathology) |
| 1 | Ovary cancer |
| 1 | Paclitaxel (adverse effects) |
| 1 | Paclitaxel (therapeutic use) |
| 1 | Patient Reported Outcome Measures |
| 1 | Patient Selection |
| 1 | Phase III trial |
| 1 | Platinum |
| 1 | Platinum Compounds |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | Prognosis |
| 1 | Self Report |
| 1 | Societies, Medical |
| 1 | Topotecan (adverse effects) |
| 1 | Topotecan (therapeutic use) |
| 1 | Treatment resistance |
| 1 | Vascular endothelium growth factor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Felix Hilpert"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Felix Hilpert" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Felix Hilpert
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
